Canaccord Genuity Group Cuts Omada Health (NASDAQ:OMDA) Price Target to $22.00

Omada Health (NASDAQ:OMDA) had its price target lowered by Canaccord Genuity Group from $28.00 to $22.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

OMDA has been the subject of several other research reports. Evercore lifted their price target on shares of Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Omada Health in a research note on Thursday, January 22nd. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Omada Health in a research report on Thursday, January 22nd. BMO Capital Markets lowered their target price on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $26.00 price target on shares of Omada Health in a research report on Friday, January 16th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.90.

Omada Health Price Performance

Shares of Omada Health stock opened at $14.05 on Friday. The business has a 50-day simple moving average of $14.03 and a 200 day simple moving average of $18.65. Omada Health has a one year low of $10.28 and a one year high of $28.40. The firm has a market capitalization of $813.64 million and a price-to-earnings ratio of -56.20.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Insider Activity

In related news, CEO Sean P. Duffy sold 230,479 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $15.60, for a total transaction of $3,595,472.40. Following the transaction, the chief executive officer directly owned 126,644 shares in the company, valued at approximately $1,975,646.40. The trade was a 64.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Wei-Li Shao sold 5,618 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the sale, the president directly owned 69,079 shares of the company’s stock, valued at $1,114,244.27. The trade was a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 276,893 shares of company stock worth $4,336,787.

Institutional Trading of Omada Health

A number of hedge funds have recently bought and sold shares of OMDA. Strs Ohio purchased a new position in Omada Health in the third quarter worth $38,000. Raymond James Financial Inc. purchased a new stake in shares of Omada Health during the 2nd quarter valued at $32,000. Quarry LP bought a new stake in shares of Omada Health during the 4th quarter worth $29,000. TD Waterhouse Canada Inc. purchased a new position in shares of Omada Health in the 4th quarter worth about $32,000. Finally, Rakuten Investment Management Inc. purchased a new position in shares of Omada Health in the 3rd quarter worth about $49,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.